Skip to main content

Table 2 Primer sequences for candidate genes.

From: Screening of functional and positional candidate genes in families with common variable immunodeficiency

Gene

Exon

Forward primer

Reverse primer

bp§

°C§

APRIL

1

CCTTGCTACCCCACTCTTGA

TCTCTTGCACCCCCTTGAA

402

62

 

2

CTGGGAAAAGGTGCGTGAGA

TGAGGAGAGAAGGAGGGAATC

337

62

 

3

AGCAGCGTGGGGATTGTAA

CTCAGGTGCTTTTTGGTTCTTT

268

62

 

4

AAGTGGATGCGGCTGAGATT

GGGAAGGGAGATGTTGAAGAA

536

62

 

5

CATACCAAACCCAGCAGAC

GTTTCCAACCTCCCTCCTA

335

62

 

6

GCGGGTCTGAGGAGTGAAGT

AGTCTAGGGGGTGGGAATGA

415

62

BCMA

1

GTCTATCTCCCTGGCACCTCTCAC

CACTGCCTTGCTTCCTTTCTCTTT

685

55

 

2

CGGGAGGCTGAGGCAGGAG

TCGAAAGGGCTGTAACGAAGTGAA

451

55

 

3

TCCCGACTGCTCTGTAGGCTAACG

TTCTTTCCCCCTCCCACCTTTCTC

797

57

CCL18

1

ATCCCTGGGTGCTTCCAACTC

TGCCCAGGGAGCCATCAA

414

57

 

2

CCAAGCGGTGATATCTCCCAGTTC

AGGCCTTCCCCAAATGTCTCAGA

477

60

 

3a

GAGGCCCCTGCAGTGTTTTGTG

CTGGGCATAGCAGATGGGACTCTT

498

60

 

3b

GCAGGGGCCACAGGATTCC

TGCCCCTTTTCATATTTCCCTACT

680

57

IL10

1

GTGCCGGGAAACCTTGATTGTGG

GGGGGAATAGGTGTTGGGGATGG

435

60

 

2 and 3

GGGCATCAAAAAGACCGCATTTCA

CCCCCAACGCCTGCTCAAAGA

763

60

 

4

CCACCAGCTTGTCCCCTAAGTGTG

TGGCCGGCCAGCCTAACC

404

59

 

5

AGCATGAGGGAGGGGAGCCTATTT

GCGCCCGGCCTAGAACCAA

781

57

IL10RA

1

CGCTAGCGCCCCAGGACAG

GTTTGCGGGTTGGGGGTTTG

545

64

 

2

ATGTGCCCACTCTGCCCCTTACG

GGGCCCTCAGGCACTCACTTCATT

377

61

 

3

GGGCTGTCCCAGTTTCTCCCAATG

CCCAACCCACCCCAAGACCTCTC

542

61

 

4

CAAAGTCTCGGCGGGGACACC

CCTCCTCTGCCCACCCACCAT

388

61

 

5

AGGCCCACCAGCTCTCAGTGTCC

CCAGGTGCACGCGTTTTGGATT

302

60

 

6

CTTGGGCCACTCACTGAATGGTT

CCCACAGCGCTTGATGAAGGTAT

404

60

 

7

CCTTCCCCGGCAGCACTGG

GCAGAGGAGCAGGCATGGCTAAAA

1048

63

IL10RB

1

GCGCCTTTCAAAGCTTGCGAGGAT

GGCCGTGGCGTTTGCATCTTCTCT

442

65

 

2

ACCCACGTGGCCTTTGAAGACAT

GTGGCCACGAGAATTTCCCAGAC

416

60

 

3

CCAGTCAGCCTCAGGGAGAC

GGGCCCCAACATAGTCACAT

486

54

 

4

ACTTCCGTGGACTAATTGTTCTGC

CTTCAGGGAGGGAAAGGTCTG

494

55

 

5

AGTCCCCCAAAGTGCTGTGATTAC

GGGCGATAGATTTCTGAACTGAGC

575

57

 

6

TCTGAGACGTCCCCCAAGATAAAC

TGGGCAGCCCTAACTAGAAAGGAA

359

57

 

7

CCAGCCAGGAGTTCTGTGAAAA

TAGATGTGGGGCTGGCTCAGAT

382

57

IL21

1 and 2

AGTTACTCACATTCATCCAT

CTGTCTCAGCAATACTACTT

736

50

 

3

GAAATAGAGGATTGGGAAAG

GGTAAGGAAGACACCAGCAG

345

50

 

4 and 5

TACAAGGACTTTTTCCATTG

GACTTTGCACACTTATGAGT

510

50

IL21R

1

TCTCTGCTGAGTGACCGTAAG

TTCCTTCCCCAGCCCGCTACA

675

58

 

2

CAGCAAGGGCAAAATAGTCAG

TGTCTACCGCTTCTGTTTCAT

898

57

 

3

TTGGGACATTTTCAGCATAGC

ACCATTCATGGGAAGCGTGTA

863

59

 

4

TGCTGCCCTAAATGAGGTAGT

AAAATTAGCTGGGTGTAGTGG

610

59

 

5

AGATGGGGTTTCACCGTGTTA

TGCTCGTGCCCTTGGTCTCTG

699

55

 

6

TTGCTAAGATGTCTGTAGTTA

GGGAAATGGGTCTGGGGTAGA

1067

55

 

7

CCCTGTTTTTCAGACGAGATA

TTCAGAGGTGTGGACTATTAC

755

55

 

8

GTGAAGAGGTGGCTGTAATAG

AGATGGGGAGGCGGAGTGGTG

768

55

 

9

AGTGAACCGAGATGGCACCAC

AGGGAGGACGGCTGTTGTCAT

1270

59

  1. IBD, sporadic CVID patients with symptoms of inflammatory bowel disease; NA, not applicable.